-
公开(公告)号:US20210236514A1
公开(公告)日:2021-08-05
申请号:US17255022
申请日:2019-07-03
发明人: Yogesh DANDIKER
摘要: The invention relates to a sprayable liquid composition for transdermal delivery of testosterone and/or estradiol, and to methods of treatment using this composition.
-
公开(公告)号:US20230227448A1
公开(公告)日:2023-07-20
申请号:US18002221
申请日:2021-06-23
发明人: Yogesh DANDIKER
IPC分类号: C07D471/04
CPC分类号: C07D471/04
摘要: The invention relates to novel crystalline forms of imiquimod formed with ferulic acid, acetic acid, coumaric acid, citric acid, or tartaric acid, to methods of making these cocrystals, and to compositions containing the cocrystals.
-
公开(公告)号:US20230143438A1
公开(公告)日:2023-05-11
申请号:US18054816
申请日:2022-11-11
发明人: Yogesh DANDIKER , Maulik K. PANCHAL
CPC分类号: A61K9/7015 , A61K31/568 , A61K47/10 , A61K47/14 , A61K47/32 , A61M35/003 , A61M39/22
摘要: The invention relates to a sprayable liquid solution for the transdermal delivery of testosterone comprising testosterone, a penetration enhancer, and a film forming excipient, and to methods of treatment using this composition.
-
公开(公告)号:US20220347132A1
公开(公告)日:2022-11-03
申请号:US17761507
申请日:2020-09-17
发明人: Yogesh DANDIKER
摘要: The invention relates to a sprayable liquid solution for the local delivery of lidocaine to the epidermis (skin), gingiva, oral mucosa or mucosal lining of the pharynx, and to a method of providing local anesthesia by administering this composition. The solution comprises at least 40% w/w lidocaine, or about 2% to about 50% w/w/ lidocaine.
-
公开(公告)号:US20210128549A1
公开(公告)日:2021-05-06
申请号:US16976378
申请日:2019-02-28
IPC分类号: A61K31/485 , A61K9/50 , A61K9/00 , A61K47/34 , A61K47/38 , A61K47/12 , A61K47/10 , A61K47/36 , A61K47/32 , A61K47/14 , A61K47/22 , A61K47/26 , A61K9/20 , A61K9/28 , A61K9/16
摘要: The invention relates to a composition that can be administered orally, comprising (a) opioid multi-particulates comprising an opioid active agent, and an abuse resistant release controlling agent; and (b) opioid antagonist multi-particulates comprising an opioid antagonist, and a release controlling agent and/or a release delaying agent. It also relates to a liquid suspension that can be administered orally, comprising (a) opioid multi-particulates comprising an opioid active agent, and an abuse resistant release controlling agent; and/or (b) opioid antagonist multi-particulates comprising an opioid antagonist, and a release controlling agent and/or a release delaying agent; and wherein the multi-particulates are suspended in a liquid comprising a viscosity modifier and a flavoring agent. The invention also relates to kits containing these multi-particulates, and methods of making and using them.
-
公开(公告)号:US20240325350A1
公开(公告)日:2024-10-03
申请号:US18619890
申请日:2024-03-28
发明人: Yogesh DANDIKER
IPC分类号: A61K31/365 , A61K9/70 , A61K31/455 , A61K47/10 , A61K47/36
CPC分类号: A61K31/365 , A61K9/7015 , A61K31/455 , A61K47/10 , A61K47/36
摘要: The present disclosure provides a sprayable liquid composition comprising about 1% w/v to about 20% w/v spironolactone or canrenone, about 30% w/v to about 97% w/v aliphatic solvent, about 1% w/v to about 10% w/v water, one or more film forming excipients, wherein the film forming excipient has a solubility in water at a pH between 1 and 10, and a penetration enhancer, wherein the composition forms a washable and/or a peelable film when sprayed on a skin surface, and wherein the spironolactone does not crystallize when the composition is applied to the skin surface. The disclosure also provides a method of treating acne, male and female pattern hair loss, hirsutism, hidradenitis suppurativa, polycystic ovary syndrome (PCOS), or combinations thereof in a subject in need thereof, the method comprising topically applying the composition described herein as a spray to a skin surface of the subject.
-
公开(公告)号:US20240148640A1
公开(公告)日:2024-05-09
申请号:US18502863
申请日:2023-11-06
发明人: Yogesh DANDIKER
CPC分类号: A61K9/0014 , A61K31/222 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/32
摘要: The present disclosure provides a sprayable composition comprising about 1% w/v to about 20% w/v of oxybutynin, a penetration enhancer, at least 65% w/v of an aliphatic solvent, and a film forming excipient, wherein the film forming excipient has a solubility in water, at a pH between 1 and 10 and wherein the composition is a sprayable liquid solution that forms a protective and washable film when sprayed on skin The disclosure also provides a method of treating vasomotor symptoms, hot flashes, hyperhidrosis, osmiodrosis, incontinence, bladder spasms, pain following bladder surgery, or combinations thereof in a subject in need thereof, the method comprising topically administering to the subject the topical compositions as described herein.
-
公开(公告)号:US20220241222A1
公开(公告)日:2022-08-04
申请号:US17620015
申请日:2020-06-25
发明人: Yogesh DANDIKER , Maulik K. PANCHAL
摘要: This disclosure provides pharmaceutical compositions comprising atomoxetine, a pharmaceutically acceptable salt of atomoxetine, or a combination thereof, that can be administered to a human subject in need thereof. The disclosure also provides pharmaceutical compositions for the treatment of orthostatic hypotension.
-
公开(公告)号:US20230226028A1
公开(公告)日:2023-07-20
申请号:US18002217
申请日:2021-06-23
发明人: Yogesh DANDIKER , Sita DANDIKER
IPC分类号: A61K31/437 , A61K47/12 , A61P37/04
CPC分类号: A61K31/437 , A61K47/12 , A61P37/04
摘要: The invention relates to a method of inhibiting viral replication by topically administering imiquimod, {1-(2-methylpropyl)-1H-imidazo[4,5-c]-quinolin-4-amine} or by administering imiquimod cocrystals (made with ferulic, acetic, tartaric, citric or coumaric acid). Another aspect of the invention is a method of preventing or reducing the severity of an infection by topically administering by imiquimod, or one of these cocrystals. Another aspect is administering imiquimod or one of these cocrystals in a nasal spray.
-
公开(公告)号:US20200330397A1
公开(公告)日:2020-10-22
申请号:US16960428
申请日:2019-01-10
摘要: The invention relates to a sprayable liquid solution for the transdermal delivery of testosterone comprising testosterone, a penetration enhancer, and a film forming excipient, and to methods of treatment using this composition.
-
-
-
-
-
-
-
-
-